Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MERUS LABS INTERNATIONAL INC T.MSL

Healthcare Drug Manufacturers - Specialty & Generic
"Merus Labs International Inc is a specialty pharmaceutical company. The Company acquires and licenses novel pharmaceutical products."


TSX:MSL - Post by User

MERUS LABS INTERNATIONAL INC
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by Raza82on Feb 01, 2017 3:03pm
145 Views
Post# 25785035

BEUTEL, GOODMAN & CO REPORTS 14.12PCT PASSIVE STAKE IN MERUS

BEUTEL, GOODMAN & CO REPORTS 14.12PCT PASSIVE STAKE IN MERUS

Jan 23 (Reuters) - Beutel, Goodman & Company Ltd

* REPORTS 14.12 PERCENT PASSIVE STAKE IN MERUS LABS INTERNATIONAL INC AS OF DEC 31, 2016 - SEC FILING Source text (https://bit.ly/2iWQuA0) Further company coverage:

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities